Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hangzhou NeoVax Biotechnology
Hangzhou, Zhejiang, Chinaneovax.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead program, NPVAC-2 (NeoPep Vaccine), is under Phase 1 clinical evaluation for glioma. Early results indicate safety and preliminary signals of efficacy. Approximately 80 patients have been treated in investigator-initiated trials, with results published in international journals[3][5][2].
- Therapeutic areas
- OncologyNeurology
- Modalities
- Personalized antigen vaccineTherapeutic vaccinePeptides
- Industry
- Biotech
Beyond the preview
Go deeper on Hangzhou NeoVax Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou NeoVax Biotechnology.